Differences in Fecal Short-Chain Fatty Acids between Alcoholic Fatty Liver-Induced Cirrhosis and Non-alcoholic (Metabolic-Associated) Fatty Liver-Induced Cirrhosis. 2023

Xinlu Cao, and Oksana Zolnikova, and Roman Maslennikov, and Maria Reshetova, and Elena Poluektova, and Arina Bogacheva, and Maria Zharkova, and Vladimir Ivashkin
Department of Internal Medicine, Gastroenterology and Hepatology, Sechenov University, 119435 Moscow, Russia.

The objective of this study was to investigate the metabolic activity of the gut microbiota in cirrhosis due to different variants of fatty liver disease (alcoholic vs. non-alcoholic [metabolic-associated] one [AFLD and MAFLD]). The present study included 24 patients with alcoholic liver cirrhosis, 16 patients with MAFLD-related cirrhosis, and 20 healthy controls. The level and spectrum of short-chain fatty acids (SCFAs) were determined via gas-liquid chromatography. All patients with cirrhosis showed a decrease in the total content of SCFAs (p < 0.001) and absolute content of acetate (p < 0.001), propionate (p < 0.001), butyrate (p < 0.001), and isovalerate (p < 0.001). In MAFLD cirrhosis, the metabolic activity of the microbiota was significantly altered compared to patients with alcoholic cirrhosis, as evidenced by a lower total SCFA content (p < 0.001) and absolute content of acetate (p < 0.001), propionate (p < 0.001), and butyrate (p < 0.001); a higher relative content of isovalerate (p < 0.001); and a higher IsoCn/Cn ratio (p < 0.001). Various clinical and laboratory parameters correlate differently with fecal SCFAs and their fractions in cirrhosis due to AFLD and MAFLD. SCFA-producing metabolic activity is reduced more in MAFLD cirrhosis than in alcoholic cirrhosis. According to the etiological factors of cirrhosis, disorders of this metabolic activity may be involved in different pathogenetic pathways.

UI MeSH Term Description Entries

Related Publications

Xinlu Cao, and Oksana Zolnikova, and Roman Maslennikov, and Maria Reshetova, and Elena Poluektova, and Arina Bogacheva, and Maria Zharkova, and Vladimir Ivashkin
June 2020, CNS oncology,
Xinlu Cao, and Oksana Zolnikova, and Roman Maslennikov, and Maria Reshetova, and Elena Poluektova, and Arina Bogacheva, and Maria Zharkova, and Vladimir Ivashkin
March 2023, Nutrients,
Xinlu Cao, and Oksana Zolnikova, and Roman Maslennikov, and Maria Reshetova, and Elena Poluektova, and Arina Bogacheva, and Maria Zharkova, and Vladimir Ivashkin
February 2024, World journal of gastroenterology,
Xinlu Cao, and Oksana Zolnikova, and Roman Maslennikov, and Maria Reshetova, and Elena Poluektova, and Arina Bogacheva, and Maria Zharkova, and Vladimir Ivashkin
March 2023, Diabetes & metabolism journal,
Xinlu Cao, and Oksana Zolnikova, and Roman Maslennikov, and Maria Reshetova, and Elena Poluektova, and Arina Bogacheva, and Maria Zharkova, and Vladimir Ivashkin
January 2020, Bioscience of microbiota, food and health,
Xinlu Cao, and Oksana Zolnikova, and Roman Maslennikov, and Maria Reshetova, and Elena Poluektova, and Arina Bogacheva, and Maria Zharkova, and Vladimir Ivashkin
January 2021, Translational gastroenterology and hepatology,
Xinlu Cao, and Oksana Zolnikova, and Roman Maslennikov, and Maria Reshetova, and Elena Poluektova, and Arina Bogacheva, and Maria Zharkova, and Vladimir Ivashkin
April 2021, Aging,
Xinlu Cao, and Oksana Zolnikova, and Roman Maslennikov, and Maria Reshetova, and Elena Poluektova, and Arina Bogacheva, and Maria Zharkova, and Vladimir Ivashkin
September 2022, Experimental and therapeutic medicine,
Xinlu Cao, and Oksana Zolnikova, and Roman Maslennikov, and Maria Reshetova, and Elena Poluektova, and Arina Bogacheva, and Maria Zharkova, and Vladimir Ivashkin
October 2010, Progress in lipid research,
Xinlu Cao, and Oksana Zolnikova, and Roman Maslennikov, and Maria Reshetova, and Elena Poluektova, and Arina Bogacheva, and Maria Zharkova, and Vladimir Ivashkin
April 2024, Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology,
Copied contents to your clipboard!